About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Hydroxyurea Optimisation in Sickle Cell Disease | Clinical Trials | Clareo Health

Back to clinical trial search

Not Yet RecruitingNCT07543289

Hydroxyurea Optimisation in Sickle Cell Disease

The wide interindividual variability in clinical response to hydroxyurea therapy in the management of sickle cell disease has limited its use. These variabilities have been linked to differences in ph...

Lead sponsor: Ochuko Orherhe•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Ochuko M. Orherhe, M.Phil.

CONTACT

+2348051589453 [email protected]

Babatunde A Adeagbo, PhD

CONTACT

+2348069019643 [email protected]

Sponsors

Lead Sponsor

Ochuko Orherhe

Collaborators

Consortium for Advanced Research Training in Africa (CARTA)
Obafemi Awolowo University
Obafemi Awolowo University Teaching Hospital

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Patients with confirmed diagnosis of sickle cell disease (SCD) (e.g., HbSS, HbSC) and of Nigerian descent.
•Patients currently on hydroxyurea therapy or hydroxyurea-naive patients who are willing to commence hydroxyurea therapy.
•Patients whose genotypic profile for the major metabolising enzymes has been previously done e.g. CYP2D6.
•Patients who consent to be part of the study

Exclusion Criteria

•Patients with severe comorbidities that may significantly alter pharmacokinetics (e.g., advanced renal or hepatic failure)
•Patients in acute crisis at the time of sampling.
•Patients with documented poor adherence to other medications previously on.
•Pregnant females and lactating mothers.

Related studies

RECRUITINGPhase 3

Efficacy and Safety of Tocilizumab for Acute Chest Syndrome Treatment in Patients With Sickle Cell Disease

NCT06818266 · Sickle Cell Disease, Acute Chest Syndrome

Peripheral Arterial Tonometry and Neurocognition in Sickle Cell Disease

NCT06477289 · Sickle Cell Disease

RECRUITINGPhase 3

A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

NCT06612268 · Sickle Cell Disease

ATHNdataset Registry

NCT06820515 · Hemophilia, Thrombosis, and more

RECRUITINGPhase 3

Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease

NCT07247188 · Sickle Cell Disease

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 30, 2026Terms

Trial snapshot

StatusNOT_YET_RECRUITING

Phase—

Enrollment100

Start dateMay 2026

Last updatedApr 30, 2026

Condition

Sickle Cell Disease

Locations shown

Obafemi Awolowo University Teaching Hospital Complex

Ile-Ife, Osun State

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 30, 2026Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions